Effect of pemafibrate for hypertriglyceridemia with erectile dysfunction

Effect of pemafibrate for hypertriglyceridemia with erectile dysfunction - P-FED

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059746

Enrollment

Registered

2025-11-12

Start date

2025-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia and Erectile Dysfunction

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria will be eligible for this study 1)Patients who have been prescribed pemafibrate based on a physician's diangnosis 2)Patients diagnosed with erectile dysfunction 3)Patients who have provided written informed consent to participate in this study 4)Male patients aged 18 years or older at the time of the consent

Exclusion criteria

Exclusion criteria: Patients who meet any of the following criteria will be excluded from participation in this study: 1. Patients judged by the principal investigator to be unsuitable for enrollment in the study 2. Patients with psychogenic erectile dysfunction

Design outcomes

Primary

Measure	Time frame
Rate of Change in Serum Triglyceride Levels Before and After Pemafibrate Administration	—

Secondary

Measure	Time frame
1)Blood test parameters before and after pemafibrate administration (free testosterone, HDL-C, LDL-C, EPA/AA ratio, sd LDL-C, MDA-LDL) 2)Pulse wave velocity (PWV) and carotid intima-media thickness (IMT) before and after pemafibrate administration 3)Erectile function assessed using questionnaires (Sexual Health Inventory for Men [SHIM], Erection Hardness Score [EHS])	—

Countries

Japan

Contacts

Public ContactHaruaki Sasaki

Showa Medical University Fujigaoka Hospital Department of Urology

hsasaki@med.showa-u.ac.jp+81-45-971-1151

Outcome results